In a filing, Fennec Pharmaceuticals Inc revealed its 10% Owner Southpoint Capital Advisors LP unloaded Company’s shares for reported $1.28 million on Nov 14 ’25. In the deal valued at $8.00 per share,160,100 shares were sold. As a result of this transaction, Southpoint Capital Advisors LP now holds 3,850,000 shares worth roughly $33.69 million.
Then, Southpoint Capital Advisors LP sold 85,918 shares, generating $755,193 in total proceeds. Upon selling the shares at $8.79, the 10% Owner now owns 3,764,082 shares.
Before that, Raykov Rosty sold 10,000 shares. Fennec Pharmaceuticals Inc shares valued at $81,000 were divested by the Director at a price of $8.10 per share. As a result of the transaction, Raykov Rosty now holds 82,318 shares, worth roughly $0.72 million.
Cantor Fitzgerald upgraded its Fennec Pharmaceuticals Inc [FENC] rating to an Overweight from a a Neutral in a research note published on November 22, 2022; the price target was increased to $12 from $9. A number of analysts have revised their coverage, including CapitalOne’s analysts, who began to cover the stock in early September with a ‘”an Overweight”‘ rating. Cantor Fitzgerald started covering the stock on June 05, 2020. It rated FENC as “an Overweight”.
Price Performance Review of FENC
On Monday, Fennec Pharmaceuticals Inc [NASDAQ:FENC] saw its stock jump 11.32% to $8.75. Over the last five days, the stock has gained 13.93%. Fennec Pharmaceuticals Inc shares have risen nearly 95.31% since the year began. Nevertheless, the stocks have risen 38.45% over the past one year. While a 52-week high of $9.92 was reached on 10/06/25, a 52-week low of $3.96 was recorded on 04/09/25.
Levels Of Support And Resistance For FENC Stock
The 24-hour chart illustrates a support level at 8.13, which if violated will result in even more drops to 7.52. On the upside, there is a resistance level at 9.18. A further resistance level may holdings at 9.62.
How much short interest is there in Fennec Pharmaceuticals Inc?
A steep rise in short interest was recorded in Fennec Pharmaceuticals Inc stocks on 2025-10-31, dropping by -0.32 million shares to a total of 0.98 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 1.3 million shares. There was a decline of -32.93%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 11, 2018 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating.
